1-(2-chloropyridin-4-yl)-3-(dimethylamino)prop-2-en-1-one | 164658-38-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-chloropyridin-4-yl)-3-(dimethylamino)prop-2-en-1-one
• 英文别名: 3-dimethylamino-1-(2-chloro-4-pyridyl)-2-propen-1-one；1-(2-chloro-pyridin-4-yl)-3-dimethylamino-propenone；3-Dimethylamino-1-(2-chloro4-pyridyl)-2-propen-1-one
• CAS: 164658-38-2
• 化学式: C₁₀H₁₁ClN₂O
• 分子量: 210.663
• InChiKey: WKDCWLRNCQXYCU-UHFFFAOYSA-N

物化性质

• 沸点：
  327.8±42.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-chloropyridin-4-yl)-3-(dimethylamino)prop-2-en-1-one 在 sodium ethanolate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 生成 3-[[4-[2-(3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridin-4-yl]pyrimidin-2-yl]amino]benzenesulfonamide
  参考文献：
  名称：

  Identification of pyrimidine derivatives as hSMG-1 inhibitors

  摘要：

  hSMG-1 kinase plays a dual role in a highly conserved RNA surveillance pathway termed nonsense-mediated RNA decay (NMD) and in cellular genotoxic stress response. Since deregulation of cellular responses to stress contributes to tumor growth and resistance to chemotherapy, hSMG-1 is a potential target for cancer treatment. From our screening efforts, we have identified pyrimidine derivatives as hSMG-1 kinase inhibitors. We report structure-based optimization of this pan-kinase scaffold to improve its biochemical profile and overall kinome selectivity, including mTOR and CDK, to generate the first reported selective hSMG-1 tool compound. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.107
• 作为产物：
  描述：

  2-氯-4-乙酰吡啶 生成 1-(2-chloropyridin-4-yl)-3-(dimethylamino)prop-2-en-1-one
  参考文献：
  名称：

  [EN] SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  [FR] DIAZABICYCLOHEPTANES SUBSTITUES ET LEUR UTILISATION COMME INHIBITEURS DE LA PROTEINE KINASE

  摘要：

  本发明涉及治疗性的重氮双环吡啶类化合物及其在治疗关节炎、类风湿关节炎、银屑病性关节炎或骨关节炎、器官移植、急性移植或异种移植和同种移植排斥、缺血再灌注损伤、移植耐受诱导、多发性硬化症、炎症性肠病、溃疡性结肠炎、克罗恩病、狼疮、移植物抗宿主病、T细胞介导的超敏反应疾病、接触性超敏反应、延迟型超敏反应、对麸质敏感性肠病、1型糖尿病、银屑病、接触性皮炎、Hashimoto甲状腺炎、Sjogren综合症、自身免疫性甲状腺功能亢进症、Graves'病、Addison病、自身多腺体疾病、自身性脱发、恶性贫血、白癜风、自身性垂体功能减退症、格林-巴雷综合征、自身免疫疾病、肾小球肾炎、血清病、荨麻疹、呼吸道过敏、哮喘、花粉症、过敏性鼻炎、皮肤过敏、硬皮病、真菌病、急性炎症反应、急性呼吸窘迫综合征、皮肌炎、斑秃、慢性光化性皮炎、湿疹、Behcet病、掌跖症病、脓皮病、塞扎里综合征、特应性皮炎、系统性硬化症、硬皮病、2型糖尿病和PKCθ或其他PKC家族激酶被激活、过度表达或促进肿瘤生长或肿瘤细胞存活、T细胞白血病、胸腺瘤、T和B细胞淋巴瘤、结肠癌、乳腺癌和肺癌或对化疗药物具有抗性的治疗中的应用。

  公开号：

  WO2005070934A1

文献信息

• 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
  申请人：Skolnick Phil

  公开号：US20050245517A1

  公开（公告）日：2005-11-03

  The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABA A receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA A receptors.

  本发明提供了具有化学结构为公式I的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮，其在2-和4-吡啶基环上至少有一个取代基。该发明进一步提供了应用公式I中的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮的组合物和方法，以调节GABA和GABAA受体生理学，引发哺乳动物主体中的治疗反应，缓解神经系统或精神障碍，包括中风、头部创伤、癫痫、疼痛、偏头痛、情绪障碍、焦虑、创伤后应激障碍、强迫性障碍、躁狂、双相障碍、精神分裂症、癫痫发作、抽搐、耳鸣、包括阿尔茨海默病、肌萎缩侧索硬化症和帕金森病在内的神经退行性疾病、亨廷顿舞蹈症、抑郁症、双相障碍、躁狂、三叉神经痛和其他神经痛、神经痛、高血压、脑缺血、心律失常、肌张力过高、物质滥用、肌阵挛、本体震颤、运动障碍和其他由GABA和/或GABAA受体介导的神经精神障碍。
• Pyrimidineamine derivatives and processes for the preparation thereof
  申请人：Ciba-Geigy Corporation

  公开号：US05612340A1

  公开（公告）日：1997-03-18

  N-phenyl-2-pyrimidineamine derivatives of formula (I) wherein the substituents are as defined in claim 1 are described. Those compounds can be used for example, in the treatment of tumour diseases. ##STR1##

  本文描述了公式（I）中取代基如权利要求1所定义的N-苯基-2-嘧啶胺衍生物。这些化合物可以用于例如治疗肿瘤疾病。 ##STR1##
• Cyclic compounds and compositions as protein kinase inhibitors
  申请人：IRM LLC

  公开号：US20040235841A1

  公开（公告）日：2004-11-25

  The invention provides a novel class of cyclic compounds, pharmaceutical compositions comprising such cyclic compounds and methods of using such compounds to treat or prevent diseases and disorders associated with cyclin-dependent kinases (CDKs) activity, particularly diseases associated with the activity of CDK2 and CDK5.

  该发明提供了一种新型环状化合物类，包括这种环状化合物的药物组合物和使用这些化合物治疗或预防与细胞周期依赖性激酶（CDKs）活性相关的疾病和障碍的方法，特别是与CDK2和CDK5活性相关的疾病。
• Pharmacologically active pyrimidineamine derivatives and processes for
  申请人：Novartis Corporation

  公开号：US05705502A1

  公开（公告）日：1998-01-06

  Described are N-phenyl-2-pyrimidineamine derivatives of formula I ##STR1## wherein R.sub.1 is a substituted cyclic radical, the cyclic radical being bonded at a ring carbon atom in each case and being selected from phenyl, pyridyl, pyrazinyl, thiazolyl, pyrimidinyl, pyridazinyl and imidazolyl, and the substituents of the above-mentioned cyclic radical being selected from one or more of the groups halogen, cyano, carbamoyl, --C(.dbd.O)--OR.sub.3, --C(.dbd.O)--R.sub.4, --SO.sub.2 --N(R.sub.5)--R.sub.6, --N(R.sub.7)--R.sub.8, --OR.sub.9 and fluorine-substituted lower alkyl, wherein R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino; and R.sub.2 is selected from halogen, cyano, carbamoyl, --C(.dbd.O)--OR.sub.10, --C(.dbd.O)--R.sub.11, --SO.sub.2 --N(R.sub.12)--R.sub.13, --N(R.sub.14)--R.sub.15, --OR.sub.16 and fluorine-substituted lower alkyl, wherein R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15 and R.sub.16 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino. Those compounds can be used, for example, in the treatment of tumour diseases.

  本文介绍了公式I的N-苯基-2-嘧啶胺衍生物，其中R₁是取代的环状基团，环状基团在每种情况下都与一个环碳原子键合，并且从苯基，吡啶基，吡嗪基，噻唑基，嘧啶基，吡嗪嗪基和咪唑基中选择，上述环状基团的取代基从卤素，氰基，氨基甲酰，--C(.dbd.O)--OR₃，--C(.dbd.O)--R₄，--SO₂--N(R₅)--R₆，--N(R₇)--R₈，--OR₉和氟代低烷基中选择，其中R₃，R₄，R₅，R₆，R₇，R₈和R₉各自独立地为氢或未取代或取代为单烷基氨基或二烷基氨基的低烷基；而R₂从卤素，氰基，氨基甲酰，--C(.dbd.O)--OR₁₀，--C(.dbd.O)--R₁₁，--SO₂--N(R₁₂)--R₁₃，--N(R₁₄)--R₁₅，--OR₁₆和氟代低烷基中选择，其中R₁₀，R₁₁，R₁₂，R₁₃，R₁₄，R₁₅和R₁₆各自独立地为氢或未取代或取代为单烷基氨基或二烷基氨基的低烷基。这些化合物可以用于治疗肿瘤疾病。
• Pharmacologically active pyridine derivatives and processes for the
  申请人：Novartis Corporation

  公开号：US05728708A1

  公开（公告）日：1998-03-17

  N-phenyl-2-pyrimidineamine derivatives of formula I ##STR1## wherein the substituents are as defined in claim 1 and the derivatives of formula I can be used, for example, in the treatment of tumour diseases.

  公式I中的N-苯基-2-嘧啶胺衍生物 ##STR1## 其中取代基如权利要求1所定义的那样，公式I的衍生物可以用于例如治疗肿瘤疾病。